Radiopharm Theranostics Ltd RADX
Radiopharm Theranostics Ltd (Nasdaq: RADX) is an oncology drug developer. Its lead program, RAD101 (18F-fluoropivalate, FASN-targeting PET imaging agent), is in Phase 2 for diagnosis of suspected recurrent brain metastases from solid tumors. Its next catalyst on record is RAD101: Radiopharm expects to initiate Phase 3 imaging trial of RAD101 in 1Q27. (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RAD101 — Radiopharm expects to initiate Phase 3 imaging trial of RAD101 in 1Q27. (Q1 2027). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RAD101 | brain metastases imaging (diagnostic PET, IND pathway) | radiopharmaceutical | Phase 2 |
| RAD204 (Lu177 Nano-mAb PD-L1) | non-small cell lung cancer | radiopharmaceutical | Phase 1 |
| RAD202 (Lu177 Nano-mAb HER2) | HER2 breast and gastric cancer | radiopharmaceutical | Phase 1 |
| RAD301 (68Ga-Trivehexin avb6-integrin imaging) | pancreatic cancer imaging | radiopharmaceutical | Phase 1 |
| RAD402 (Tb161 PSA-mAb) | metastatic or locally advanced prostate cancer | radiopharmaceutical | Phase 1 |
| RV-01 (B7H3 mAb, Radiopharm Ventures) | solid tumors | radiopharmaceutical | Phase 1 |
| RAD302 (Lu177 Trivehexin) | pancreatic, head-neck and lung cancer | radiopharmaceutical | Pre-clinical |
| RAD102 (pivalate therapeutic) | brain tumors | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- Oct 30, 2026n/a Radiopharm announced successful completion of End-of-Phase 2 meeting with FDA for RAD101 in October 2026.
In October 2026, the Company announced the successful completion of an EOP2 meeting with the FDA for RAD101 for the detection of brain metastases.
Filing - Oct 1, 2026n/a Company announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101 for the detection of brain metastases.
In October 2026, the Company announced the successful completion of an EOP2 meeting with the FDA for RAD101 for the detection of brain metastases.
Filing - n/a Radiopharm completed successful end-of-phase 2 meeting with FDA for RAD101 in recurrent brain metastases.
In October 2026, the Company announced the successful completion of an EOP2 meeting with the FDA for RAD101 for the detection of brain metastases.
Filing
16 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.